Genentech, a member of the Roche Group, has announced topline results from the Phase II CT388-103 trial evaluating its dual GLP-1/GIP receptor agonist CT-388 in people with obesity. At the highest tested dose of 24 mg, the once-weekly subcutaneous injectable achieved a placebo-adjusted mean weight loss of 22.5% over 48 weeks, with over half of treated participants achieving resolution of obesity. These results arrive ahead of Genentech’s planned Phase III program, set to launch within the current quarter.

The announcement firmly positions CT-388 within the accelerating race for next-generation incretin therapies, where pharmaceutical companies are not only chasing weight loss magnitude but also sustainability, tolerability, and broader metabolic benefit. However, as enthusiasm builds, so too do the questions—particularly around trial design choices, regulatory alignment, and what, if anything, truly differentiates Genentech’s candidate from those of Novo Nordisk or Eli Lilly.

What CT-388’s dual receptor strategy reveals about the next wave of obesity drug development

Genentech’s CT-388 belongs to the increasingly crowded class of dual agonists targeting glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The therapeutic premise is not new: Eli Lilly’s tirzepatide (Mounjaro/Zepbound) already validated the GLP-1/GIP co-agonist model in type 2 diabetes and obesity, with peak weight loss figures exceeding 20% in some studies. However, Genentech’s results suggest that CT-388 may push this ceiling further, at least under trial conditions.

What differentiates CT-388 on a mechanistic level is its bias towards minimal β-arrestin recruitment, which industry analysts interpret as a strategy to reduce receptor desensitization and prolong pharmacological activity. This subtlety could impact tolerability and dosing sustainability—key challenges in real-world settings where gastrointestinal events remain a leading cause of treatment discontinuation.

The absence of a weight loss plateau at 48 weeks and the dose-response clarity are particularly notable. These observations suggest continued therapeutic potential beyond the study window, which is likely to be a core narrative Genentech emphasizes in Phase III trial design. By avoiding an early plateau, CT-388 could argue for a longer duration of efficacy than current market leaders, especially if sustained weight loss correlates with reduced cardiometabolic events.

What this changes for regulatory watchers and trial endpoints in obesity drug pipelines

From a regulatory perspective, the Phase II data puts CT-388 on a fast track, but it also raises expectations for Genentech’s forthcoming Enith1 and Enith2 Phase III trials. As obesity moves into mainstream therapeutic territory, regulatory agencies are tightening scrutiny—not only around absolute weight loss figures, but also comorbidity resolution, patient-reported outcomes, and long-term safety.

The Phase II trial included participants with a BMI ≥30 or ≥27 with a comorbidity, excluding individuals with type 2 diabetes. This population selection allows for a cleaner efficacy readout but leaves questions about translatability to mixed patient cohorts in real-world clinical practice. Genentech appears to be addressing this gap through its parallel CT388-104 study in participants with obesity or overweight and type 2 diabetes, which will be watched closely for durability, glucose control, and cardiometabolic outcomes.

One metric likely to catch the eye of regulators and payers is that 73% of prediabetic participants reverted to normoglycemia on the 24 mg dose, compared to just 7.5% on placebo. While not a formal primary endpoint, this result offers a potential path toward expanded indications or bundled reimbursement strategies targeting both obesity and diabetes prevention.

What clinicians are likely to scrutinize in terms of durability, dropout rates, and tolerability

Clinicians evaluating CT-388’s clinical profile will look beyond weight loss magnitude to three critical parameters: tolerability, durability of response, and adherence. Genentech reported that the treatment was generally well-tolerated, with mild-to-moderate gastrointestinal events in line with class expectations. The treatment discontinuation rate was 5.9%, which compares favorably with existing GLP-1 receptor agonists where discontinuation rates often exceed 10% in practice.

However, the interpretation of tolerability remains nuanced. Real-world adherence to weekly injections depends on not just tolerability but also dosing complexity and patient support infrastructure, areas where Genentech’s late entry may force it to develop differentiated service models if it hopes to compete with the market incumbents.

Clinicians will also closely examine β-cell function, insulin sensitivity, and cardiovascular biomarker data, none of which were disclosed in this topline readout. Without these, it is difficult to assess whether CT-388 provides metabolic improvements beyond weight loss, which is increasingly seen as necessary for formulary inclusion and long-term uptake.

Why Genentech’s commercial strategy will need to go beyond efficacy to challenge market incumbents

The CT-388 program enters a market already reshaped by the commercial success of Novo Nordisk’s semaglutide (Wegovy/Ozempic) and Eli Lilly’s tirzepatide. Both have achieved multi-indication approvals and built robust supply chains. For Genentech, which is relatively late to the obesity pipeline, success may hinge less on efficacy margins and more on manufacturing scalability, strategic partnerships, and pricing architecture.

Unlike Novo Nordisk and Eli Lilly, Genentech does not yet have an approved GLP-1-based product on the market. This raises questions around supply chain readiness, particularly given the shortages and production bottlenecks that have plagued the class globally. If CT-388 progresses to market, Genentech may need to leverage Roche’s biologics manufacturing footprint or explore contract partnerships to avoid capacity constraints.

Moreover, Roche’s diagnostic capabilities could play a role in patient selection, risk stratification, and outcomes tracking—a potential competitive differentiator if CT-388 is deployed as part of a broader cardiometabolic care model. This may become especially important if combination strategies (e.g., with petrelintide) move into the clinic.

What remains uncertain as CT-388 advances toward Phase III trials

Despite strong topline data, several key uncertainties remain. First is the question of real-world adherence and tolerability over multiple years, especially as the weight loss curve extends beyond 48 weeks. Second is whether Genentech’s biasing strategy truly delivers long-term receptor sensitivity advantages or if the benefit diminishes over time. Third is the regulatory stance on dual agonists in combination—especially if CT-388 is pursued alongside other agents such as amylin analogues.

Finally, payer strategies will be a critical factor in CT-388’s commercial viability. With rising GLP-1 adoption already straining healthcare budgets, Genentech will likely need to show not just efficacy but also cost-offset potential through diabetes prevention, cardiovascular risk reduction, and improved quality of life metrics.

If Genentech’s bet on β-arrestin avoidance pays off with durable results and better tolerability, CT-388 could find a viable niche or even become a competitive threat in the second wave of obesity drugs. But absent that, it risks becoming yet another high-potential entrant with limited market traction in an increasingly crowded space.

  CT-388, dual agonist, Genentech, GIP, GLP-1, obesity, Phase II, Roche, semaglutide, tirzepatide, weight loss